Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA9 | Q16790 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA4 | P22748 | 3/20 | 0.57 |
| ▸ | CA6 | P23280 | 2/20 | 0.57 |
| ▸ | CA5A | P35218 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17315251 | 0.84 | CA2 (0.60) | PSIP1CA2CA1CA9CA12 | |
| SCHEMBL10060475 | 0.82 | ALDH1A1 (0.40) | CA2CA1CA9CA12CA6 | |
| SCHEMBL9908319 | 0.81 | CA2 (0.57) | PSIP1CA2MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL17342747 | 0.79 | IDO1 (0.43) | PSIP1CA2ATRATMALDH1A1 | |
| SCHEMBL1941299 | 0.79 | ALDH1A1 (0.42) | PSIP1CA2CA1CA9CA12 | |
| SCHEMBL2643474 | 0.79 | ALDH1A1 (0.42) | PSIP1CA2CA1CA9CA12 | |
| SCHEMBL4547863 | 0.79 | CA2 (0.55) | CA2CA1CA9CA12CA4 | |
| SCHEMBL15212526 | 0.79 | CA1 (0.57) | PSIP1CA2CA1CA9CA12 | |
| SCHEMBL16186188 | 0.78 | CA2 (0.60) | CA2SMN1; SMN2ALDH1A1 | |
| SCHEMBL20372777 | 0.78 | ALDH1A1 (0.44) | PSIP1CA2KDM4ESMN1; SMN2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12077555-B2 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-1861370-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006098683-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | WO | disclosed |
| EP-1663974-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050148624-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-07 | — | — | US | disclosed |
| WO-2005026124-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| EP-1484320-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148624-A1 | Jnk inhibitor | MAPK3, MAPKAPK3, MAPK1 | PSIP1 3712/4885CA2 4144/4885CA1 3996/4885 |
| US-20230084113-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | PSIP1 1730/4885CA2 3372/4885CA1 2752/4885 |
| US-20230120381-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | PSIP1 1730/4885CA2 3372/4885CA1 2752/4885 |
| US-12077555-B2 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | PSIP1 1730/4885CA2 3372/4885CA1 2752/4885 |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | PSIP1 1730/4885CA2 3372/4885CA1 2752/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | PSIP1 1730/4885CA2 3372/4885CA1 2752/4885 |
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, SERPINE1 | PSIP1 3832/4885CA2 3009/4885CA1 4709/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | PSIP1 1730/4885CA2 3372/4885CA1 2752/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | PSIP1 3913/4885CA2 81/4885CA1 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.